|Bid||12.10 x 800|
|Ask||14.99 x 900|
|Day's Range||12.65 - 13.17|
|52 Week Range||11.21 - 25.96|
|Beta (3Y Monthly)||2.97|
|PE Ratio (TTM)||11.19|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.80|
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had net income of 14 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, were 22 cents per share. The drug developer posted ...
MENLO PARK, Calif., Nov. 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat.
In 1999 Joseph Belanoff was appointed CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
MENLO PARK, Calif., Oct. 25, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its third quarter 2018 financial results and provide a.
MENLO PARK, Calif., Oct. 24, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Anyone researching Corcept Therapeutics Incorporated (NASDAQ:CORT) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...
Corcept Therapeutics Incorporated (CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that the Food and Drug Administration (FDA) has granted orphan drug status to Corcept’s selective cortisol modulator relacorilant to treat patients with pancreatic cancer. Corcept is conducting clinical trials of relacorilant in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) as a treatment for pancreatic cancer and other solid tumors.
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Corcept Therapeutics Incorporated (NASDAQ:CORT) due to its excellent fundamentals in moreRead More...
The stock has climbed 140% over the last 12 months and is now trading with a price-earnings ratio of 6.86 and a price-book ratio of 18.46. Jim Simons (Trades, Portfolio)' Renaissance Technologies is the largest guru shareholder of the company with 0.63% of outstanding shares, followed by Greenblatt with 0.04%. The stock has declined 4% over the last 12 months and is now trading with a price-earnings ratio of 18.40 and a price-book ratio of 4.56.
NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter ...
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. Portola Pharmaceuticals Inc (NASDAQ: PTLA) saw a director step up to the buy window this past week. The total of 390,000 shares of this biopharmaceutical company acquired, at per-share prices ranging from $25 to $26.95, cost the advisor more than $10.07 million.
Baker, a managing director of Sutter Hill Ventures and a director of Corcept (CORT) since 1999, bought a total of 321,159 shares from Aug. 14 through Aug. 20 for an average of $12.54 each, according to his Securities and Exchange Commission filings. S&P Capital IQ puts Baker’s stake at 4%, making him the fifth-largest shareholder in Corcept, which develops drugs that regulate the effects of the stress hormone cortisol. Not only does Baker’s buying represent his first open-market purchases of Corcept in more than two years, he had been selling the stock as recently as this spring.
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 9) Acer Therapeutics Inc (NASDAQ: ACER )(HC Wainwright reiterated ...
Corcept (CORT) delivered earnings and revenue surprises of -16.67% and -9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?